Advanced search

Filter By:

Journal Check one or more journals to show results from those journals only.

Choose more journals

Article type Check one or more article types to show results from those article types only.
Subject Check one or more subjects to show results from those subjects only.
Date Choose a date option to show results from those dates only.

Custom date range

Clear all filters
Sort by:
Showing 1–8 of 8 results
Advanced filters: Author: Stéphan Vagner Clear advanced filters

  • BRAF mutations occur frequently in melanomas, but patients generally develop resistance to agents targeting mutant BRAF; now, the persistent formation of the translation initiation complex eIF4F has been described as an indicator of multiple mechanisms of resistance that arise in BRAF-mutated tumours and as a promising therapeutic target.

    • Lise Boussemart
    • Hélène Malka-Mahieu
    • Stéphan Vagner
    Research
    Nature
    Volume: 513, P: 105-109

  • Melanoma persister cells are tolerant to anti-BRAF and anti-MEK inhibition and can trigger cancer relapse. Here the authors show that a subset of N6-methyladenosine modified mRNAs is translationally activated in persister cells. This preferential translation can be abrogated via eIF4A inhibition.

    • Shensi Shen
    • Sara Faouzi
    • Caroline Robert
    ResearchOpen Access
    Nature Communications
    Volume: 10, P: 1-14

  • Both epigenetic and splicing regulation contribute to tumor progression, but how these contributions are linked is not well understood. A new study reveals a cascade of altered gene-expression events that underlie tumor progression, wherein splicing factors Ddx5 and Ddx17 control the alternative splicing of an epigenetic factor, macroH2A1, leading to transcriptional alterations that switch tumor cells to an invasive phenotype.

    • Etienne Dardenne
    • Sandra Pierredon
    • Didier Auboeuf
    Research
    Nature Structural & Molecular Biology
    Volume: 19, P: 1139-1146

  • A variant of the IL7 gene predicts the toxicity of checkpoint inhibitors in patients with cancer, via a mechanism shared with autoimmune diseases — which could inform biomarker and treatment strategies in both of these contexts.

    • Caroline Robert
    • Stéphan Vagner
    • Xavier Mariette
    News & Views
    Nature Medicine
    Volume: 28, P: 2471-2472

  • The translational control of mRNAs during gene expression allows rapid, specific changes in the cell proteome. This Review describes the mechanisms underlying changes in mRNA translation in response to oncogenic signalling and microenvironmental stress, and how these changes can promote cancer onset, progression and resistance to anticancer therapies.

    • Lucilla Fabbri
    • Alina Chakraborty
    • Stéphan Vagner
    Reviews
    Nature Reviews Cancer
    Volume: 21, P: 558-577

  • A high serum lactate dehydrogenase (LDH) level is generally associated with an inferior outcome in patients with most tumour types. LDH is also known to have immunosuppressive and/or tumour-promoting effects, suggesting a potentially broader role for this enzyme in clinical oncology. In this Review, the authors provide a holistic overview of the current role of LDH in both cancer biology and oncology, and highlight possible areas of future research interest, including the development of novel therapies targeting LDH.

    • Giuseppina Claps
    • Sara Faouzi
    • Caroline Robert
    Reviews
    Nature Reviews Clinical Oncology
    Volume: 19, P: 749-762

  • A number of compounds, derived from bacterial fermentation products, have been found to target subunits of the spliceosome and display anticancer properties. In this Review, Valcárcel and colleagues discuss the role of splicing in cancer and how insights into the mechanism of action of these bacterial compounds might lead to the development of novel antitumour drugs.

    • Sophie Bonnal
    • Luisa Vigevani
    • Juan Valcárcel
    Reviews
    Nature Reviews Drug Discovery
    Volume: 11, P: 847-859